🇺🇸 FDA
Patent

US 10815239

Compounds useful as inhibitors of ATR kinase

granted A61KA61K31/519A61P

Quick answer

US patent 10815239 (Compounds useful as inhibitors of ATR kinase) held by Vertex Pharmaceuticals Incorporated expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/519, A61P, A61P35/00, A61P43/00